About YposKesiYposKesi (from the Greek Yposchesi, meaning 'promise') is the first French company to develop and produce gene and cell therapy products. Created in November 2016 by AFM-Téléthon and by the SPI fund managed by Bpifrance, this new company aims to make the first treatments available to patients and market them at a fair and controlled price, in accordance to the commitment made by its founders. Located in Evry (Essonne, France), this industrial platform is made up of more than 130 experts in bioproduction and has a first production building covering 5,000 m2 (formerly Généthon Bioprod). It is aiming at European leadership and, with this objective, by 2021 will bring together nearly 300 engineers, pharmacists, technicians and experts in three production buildings totaling 13,000 m2. It will thus meet the needs of AFM-Téléthon laboratories (Généthon and CECS/I-Stem), as well as those of academic and industrial biotechnology organizations, for clinical trials or post-MA (Marketing Authorization) distribution.
CEO: Alain Lamproye
12 articles with YposKesi
Partnership secures access to reserved cGMP capacity and resources at Yposkesi for manufacturing to support the global development and commercialization of Axovant’s gene therapy programs
Servier appoints Yposkesi for lentiviral vector GMP-manufacturing in CAR-T cell development technology
Service agreement gives Servier access to Yposkesi’s robust production capacity
Dr. Revah will join fellow industry panelists at the Cell and Gene Meeting on the Med in Barcelona to discuss strategies for gene therapy manufacturing, on April 23rd
With 15 years’ bioproduction and cell & gene therapy expertise, Morad El Gueddari will take charge of Yposkesi’s industrial-scale viral vector manufacturing
Yposkesi enters into agreement in principle for strategic partnership with Axovant to expand Axovant’s gene therapy manufacturing capacity
In the framework of a preferred partnership, Yposkesi plans to grant Axovant access to dedicated cGMP capacity and manufacturing resources to further support the global development and commercialization of Axovant’s AAV-based gene therapy programs
With extensive experience in gene therapy vector manufacturing, Dr. Wright, scientific co-founder and former CTO of Spark Therapeutics, will support Yposkesi’s innovation in viral vector design, production and characterization
Yposkesi Presented its Latest Progress in Viral Vectors Production at the Cell & Gene Therapy World Conference in Miami
The international Cell & Gene Therapy World conference gather nearly 1,300 industry professionals from more than 30 countries.
YposKesi Welcomes Alain Lamproye, An Expert In Industrial Bioproduction, As Its Chief Executive Officer